ARVN250117C12500
- 0.00
- 0.000.00%
Arvinas Newsroom
Arvinas Holding Company Adjusts Real Estate Strategy
Express News | Arvinas Inc - on Jan 15, Unit Enters Lease Termination Agreement With Science Park Development
BTIG Initiates Arvinas(ARVN.US) With Buy Rating, Announces Target Price $69
BofA Securities Maintains Arvinas(ARVN.US) With Buy Rating, Maintains Target Price $57
Arvinas Holding Company: Strategic Pipeline Advancements and Promising Clinical Developments Justify Buy Rating
Arvinas Shares Fall Amid Breast Cancer Drug Trial Update, CCO Departure
Express News | Arvinas: Vepdegestrant to Be Combined With Pfizer's Cdk4 Inhibitor Atirmociclib in a First-Line Phase 3 Trial Planned to Initiate in 2025
Express News | Arvinas Inc - Topline Data From Veritac-2 Phase 3 Trial Expected in 1Q25
Arvinas Updates Guidance for First- and Second-Line Phase 3 Combination Trials With Vepdegestrant, Highlights Upcoming Milestones, and Provides Corporate Update
Here Are Morgan Stanley's Key Oncology Catalysts for 2025
Arvinas, Inc.'s (NASDAQ:ARVN) Stock Retreats 27% But Revenues Haven't Escaped The Attention Of Investors
BofA Securities Maintains Arvinas(ARVN.US) With Buy Rating, Raises Target Price to $57
Analysts' Opinions Are Mixed on These Healthcare Stocks: Outset Medical (OM), Arvinas Holding Company (ARVN) and Innovent Biologics (OtherIVBXF)
Buy Rating for Arvinas Holding Company Driven by Vepdeg's Promising Potential and Market Opportunity
Barclays Maintains Arvinas(ARVN.US) With Buy Rating, Maintains Target Price $48
Express News | Guggenheim Reiterates Buy on Arvinasto Buy
Arvinas Down on Investors' Read of Lilly Data, Says BTIG
Evercore Initiates Arvinas(ARVN.US) With Buy Rating, Announces Target Price $110
Arvinas Holding Company (ARVN) Receives a Buy From Evercore ISI
Demystifying Arvinas: Insights From 5 Analyst Reviews